Considering PD–L1 as a marker associated with immunotherapy response and immune escape in NSCLC and vimentin as marker of aggressiveness, we proposed that both PD–L1 and vimentin could be analyzed to refine tumor characterization and stratification at the early stage. The gene discussed is VIM; the disease is non-small cell lung carcinoma.